poly ADP-ribose polymerase (PARP) inhibitor

Niraparib - Olaparib - Rucaparib - Talazoparib - Veliparib      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

advanced breast cancer (metastatic)

niraparib
BRAVO ongoing niraparibPhysician s choice chemotherapy BRCA-mutated NCT01905592 ongoing
olaparib
OlympiAD, 2017olaparibPhysician s choice chemotherapy BRCA-mutated HER-2 negative NCT02000622Risk of bias conclusive
talazoparib
EMBRACA ongoing talazoparibPhysician s choice chemotherapy BRCA-mutated NCT01945775 ongoing
veliparib
NCT02163694 ongoing veliparib with carboplatin and caclitaxelPlacebo with Carboplatin and Paclitaxel BRCA-mutated HER-2 negative NCT02163694 ongoing

ovarian cancer

niraparib
ENGOT-OV16/NOVA non-gBRCAniraparibplacebo NCT01847274 -
ENGOT-OV16/NOVA gBRCA, 2017niraparibplacebo BRCA-mutated NCT01847274 -
olaparib
SOLO2/ENGOT-Ov21 olaparibplacebo BRCA-mutated NCT01874353suggesting
Ledermann, 2012olaparidplacebo NCT00753545 -
rucaparib
ARIEL 4 ongoing rucaparibchemotherapyRelapsed BRCA Mutant BRCA-mutated NCT02855944 ongoing
ARIEL 3 ongoing rucaparibplaceboNCT01968213Low risk of bias ongoing